Takeshima, Takao
Nakai, Masami
Shibasaki, Yoshiyuki
Ishida, Miki
Kim, Byung-Kun
Ning, Xiaoping
Koga, Nobuyuki
Funding for this research was provided by:
Otsuka Pharmaceutical Co., Ltd. (NA)
Article History
Received: 5 December 2021
Accepted: 21 January 2022
First Online: 9 February 2022
Declarations
:
: Both trials were conducted in compliance with the International Conference on Harmonisation Good Clinical Practice Guideline and local regulatory requirements, including those related to informed consent, and were approved by an institutional review board or independent ethics committee/ethics committee.
: Not applicable.
: TT has received grants or contracts from Eisai Co., Ltd. Amgen Inc., Eli Lilly Japan K.K., Allergan Japan K.K.; consulting fees from Otsuka Pharmaceutical Co., Ltd.; honoraria for lectures from Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Amgen Inc., and Eli Lilly Japan K.K. B-KK reports personal fees from Otsuka Pharmaceutical Co., Ltd.; consultation fees from Teva Korea and Sanofi Korea; consultation and lecture fees from Lundbeck Korea; and lecture fees from Lilly Korea, Allergan Korea, SK-Pharma, and YuYu Pharma Inc. XN is a full-time employee of Teva Branded Pharmaceutical Products R&D. MN, YS, MI, and NK are full-time employees of Otsuka Pharmaceutical Co., Ltd.